High serum concentration of total inhibin in polycystic ovary syndrome

Slides:

Advertisements

Similar presentations

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Advertisements

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C) Michael W. Pankhurst,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,

Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

The normal variabilities of the menstrual cycle

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

High soluble CD44 concentration in peritoneal fluid in endometriosis

Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism

Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Comparative assessment of five serum antimüllerian hormone assays for the diagnosis of polycystic ovary syndrome Pascal Pigny, Ph.D., Elisse Gorisse,

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Iris G. Insogna, M. D. , Malinda S. Lee, M. D. , M. B. A. , Rebecca M

Impact of submucous myoma on the severity of anemia

Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach Fatemeh Bazarganipour,

Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome Héctor F. Escobar-Morreale,

Evolutionary determinants of polycystic ovary syndrome: part 1

Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis

Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea Hang Wun Raymond Li,

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Robert F. Casper, M.D. Fertility and Sterility

The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.

Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.

Andrew C. Bjonnes, M.S., Richa Saxena, Ph.D., Corrine K. Welt, M.D.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms Anastasia Tsigkou,

Ana Luiza L. Rocha, M. D. , Patrizia Carrarelli, B. Sc

Ovulation induction in women with polycystic ovary syndrome

Vaginally administered estroprogestinic decreases serum inhibin A and inhibin B levels and reduces endometrial thickness Stefano Luisi, M.D., Lavinia.

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Increased secretion of amylin in women with polycystic ovary syndrome

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Antoni J. Duleba, M.D., Ibrahim M. Ahmed, M.D. Fertility and Sterility

Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition Nancy E. Reame, Ph.D., Jane L. Lukacs,

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Serum resistin levels in women with polycystic ovary syndrome

Low serum and peritoneal fluid concentration of interferon-γ–induced protein-10 (CXCL10) in women with endometriosis Letizia Galleri, Ph.D., Stefano.

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Current evaluation of amenorrhea

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular.

Presentation transcript:

High serum concentration of total inhibin in polycystic ovary syndrome Anastasia Tsigkou, Ph.D., Stefano Luisi, M.D., Ph.D., Vincenzo De Leo, M.D., Laura Patton, M.D., Alessandra Gambineri, M.D., Fernando M. Reis, M.D., Ph.D., Renato Pasquali, M.D., Felice Petraglia, M.D. Fertility and Sterility Volume 90, Issue 5, Pages 1859-1863 (November 2008) DOI: 10.1016/j.fertnstert.2007.08.082 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (A–C) Serum concentrations of total inibin, inhibin A, and inhibin B in the control group and in two subgroups of women with PCOS: overweight (BMI >25 kg/m2) and lean. The boxes delimitate the interquartile intervals, the horizontal lines represent the medians, and the error bars indicate the ranges. ∗P<.001 vs. controls; #P<.05 vs. PCOS-overweight (Kruskal-Wallis analysis of variance and Dunn's test). (D) Lack of correlation between serum total inhibin and inhibin B levels in normal controls (r = 0.130) and PCOS patients (r = 0.042). Fertility and Sterility 2008 90, 1859-1863DOI: (10.1016/j.fertnstert.2007.08.082) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions